Shiga Toxin (Stx) Classification, Structure, and Function
暂无分享,去创建一个
[1] P. Griffin,et al. Outbreaks of non-O157 Shiga toxin-producing Escherichia coli infection: USA , 2014, Epidemiology and Infection.
[2] A. Friedrich,et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. , 2002, The Journal of infectious diseases.
[3] M. James,et al. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. , 1994, Nature structural biology.
[4] Katharina Gaus,et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells , 2007, Nature.
[5] C. Ackerley,et al. Translocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. , 1997, American journal of physiology. Gastrointestinal and liver physiology.
[6] B. Magun,et al. Ricin and Shiga Toxins: Effects on Host Cell Signal Transduction , 2011, Current topics in microbiology and immunology.
[7] S. Homans,et al. Localization of the Binding Site for the Oligosaccharide Moiety of Gb3 on Verotoxin 1 Using NMR Residual Dipolar Coupling Measurements , 2000 .
[8] K. Sandvig,et al. Endocytosis and retrograde transport of Shiga toxin. , 2010, Toxicon : official journal of the International Society on Toxinology.
[9] J. Mekalanos,et al. Iron regulation of Shiga-like toxin expression in Escherichia coli is mediated by the fur locus , 1987, Journal of bacteriology.
[10] Klaus Stark,et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.
[11] Ken Hatano,et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. , 2005, The Journal of infectious diseases.
[12] C. Ducrot,et al. Association of Virulence Genotype with Phylogenetic Background in Comparison to Different Seropathotypes of Shiga Toxin-Producing Escherichia coli Isolates , 2005, Journal of Clinical Microbiology.
[13] C. Lingwood,et al. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. , 1988, Biochemical and biophysical research communications.
[14] G. Keusch,et al. Pathogenesis of Shigella diarrhea: XVII. A mammalian cell membrane glycolipid, Gb3, is required but not sufficient to confer sensitivity to Shiga toxin. , 1994, The Journal of infectious diseases.
[15] J. Gariépy,et al. Charged and Hydrophobic Surfaces on the A Chain of Shiga-Like Toxin 1 Recognize the C-Terminal Domain of Ribosomal Stalk Proteins , 2012, PloS one.
[16] Kristian Prydz,et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum , 1992, Nature.
[17] C. Lingwood,et al. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. , 1994, The Journal of biological chemistry.
[18] J. Brown,et al. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. , 1987, The Journal of biological chemistry.
[19] D. Acheson,et al. Translocation of Shiga toxin across polarized intestinal cells in tissue culture , 1996, Infection and immunity.
[20] Mutations affecting the activity of the Shiga-like toxin I A-chain. , 1992, Biochemistry.
[21] F. Gunzer,et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. , 2003, Blood.
[22] L. Beutin,et al. Isolation of Shigella sonnei lysogenic for a bacteriophage encoding gene for production of Shiga toxin , 1999, The Lancet.
[23] D. Acheson,et al. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. , 1995, The Journal of clinical investigation.
[24] T. Takeda,et al. Serum Amyloid P Component Is the Shiga Toxin 2-neutralizing Factor in Human Blood* , 2001, The Journal of Biological Chemistry.
[25] J. Thurman,et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[26] K. Mølbak,et al. A verocytotoxin-producing E. coli outbreak with a surprisingly high risk of haemolytic uraemic syndrome, Denmark, September-October 2012. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[27] J. LaMarre,et al. Binding of Escherichia coli verotoxins to cell surface protein on wild-type and globotriaosylceramide-deficient Vero cells. , 1998, Canadian journal of microbiology.
[28] S. McEwen,et al. Associations between Virulence Factors of Shiga Toxin-ProducingEscherichia coli and Disease in Humans , 1999, Journal of Clinical Microbiology.
[29] M. Troxell,et al. Mouse Model of Hemolytic-Uremic Syndrome Caused by Endotoxin-Free Shiga Toxin 2 (Stx2) and Protection from Lethal Outcome by Anti-Stx2 Antibody , 2008, Infection and Immunity.
[30] A. Herr,et al. Shiga Toxin Binding to Glycolipids and Glycans , 2012, PloS one.
[31] M. Kim,et al. Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells , 2013, Journal of Microbiology.
[32] H. Uchida,et al. The Detection of Shiga Toxins in the Kidney of a Patient with Hemolytic Uremic Syndrome , 1999, Pediatric Research.
[33] M. P. Jackson,et al. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine , 1988, Journal of bacteriology.
[34] S. Ostroff,et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. , 1989, The Journal of infectious diseases.
[35] J. Samuel,et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice , 1993, Infection and immunity.
[36] J. Samuel,et al. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants , 1990, Infection and immunity.
[37] K. Sandvig,et al. The A‐subunit of surface‐bound Shiga toxin stimulates clathrin‐dependent uptake of the toxin , 2005, The FEBS journal.
[38] B. Binnington,et al. Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide‐containing lipid assemblies , 2008, Journal of cellular physiology.
[39] M. Smith,et al. Oral Intoxication of Mice with Shiga Toxin Type 2a (Stx2a) and Protection by Anti-Stx2a Monoclonal Antibody 11E10 , 2013, Infection and Immunity.
[40] P. Sansonetti,et al. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1 , 1988, Infection and immunity.
[41] A. Friedrich,et al. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] D. Acheson,et al. Shiga Toxin Translocation across Intestinal Epithelial Cells Is Enhanced by Neutrophil Transmigration , 2001, Infection and Immunity.
[43] A. Trofa,et al. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] A. Friedrich,et al. Shiga Toxin 1c-Producing Escherichia coli Strains: Phenotypic and Genetic Characterization and Association with Human Disease , 2003, Journal of Clinical Microbiology.
[45] L. Hoelzle,et al. Characterization of shiga toxin type 2 variant B‐subunit in Escherichia coli strains from asymptomatic human carriers by PCR‐RFLP , 2000, Letters in applied microbiology.
[46] C. Lingwood,et al. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. , 1987, The Journal of biological chemistry.
[47] G. Frankel,et al. Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture , 2004, Cellular microbiology.
[48] L. Johannes,et al. Functionally different pools of Shiga toxin receptor, globotriaosyl ceramide, in HeLa cells , 2006, The FEBS journal.
[49] S. Kurosawa,et al. Shiga Toxins and the Pathophysiology of Hemolytic Uremic Syndrome in Humans and Animals , 2012, Toxins.
[50] V. L. Tesh,et al. Distinct Physiologic and Inflammatory Responses Elicited in Baboons after Challenge with Shiga Toxin Type 1 or 2 from Enterohemorrhagic Escherichia coli , 2010, Infection and Immunity.
[51] H. Collins,et al. Morphologic evaluation of the effects of Shiga toxin and E coli Shiga-like toxin on the rabbit intestine. , 1986, The American journal of pathology.
[52] R. Spooner,et al. How ricin and Shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum. , 2012, Current topics in microbiology and immunology.
[53] Randy J. Read,et al. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli , 1992, Nature.
[54] L. Johannes,et al. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. , 2006, Kidney international.
[55] M. McKee,et al. Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells , 1995, Infection and immunity.
[56] J. Gariépy,et al. A Role for the Protease-sensitive Loop Region of Shiga-like Toxin 1 in the Retrotranslocation of Its A1 Domain from the Endoplasmic Reticulum Lumen* , 2005, Journal of Biological Chemistry.
[57] R. Dietrich,et al. Identification and Characterization of a New Variant of Shiga Toxin 1 in Escherichia coli ONT:H19 of Bovine Origin , 2022 .
[58] J. R. Peterson,et al. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[59] M. McKee,et al. Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells , 1995, Infection and immunity.
[60] R. Field,et al. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. , 1998, Biochemistry.
[61] M. Breimer,et al. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. , 1991, Journal of biochemistry.
[62] M. James,et al. Structure of Shiga Toxin Type 2 (Stx2) from Escherichia coli O157:H7* , 2004, Journal of Biological Chemistry.
[63] A. O’Brien,et al. Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C‐terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer , 2002, Molecular microbiology.
[64] A. Shevchenko,et al. Glycosphingolipid Requirements for Endosome‐to‐Golgi Transport of Shiga Toxin , 2009, Traffic.
[65] R. Norel,et al. Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins. , 1996, Chemistry & biology.
[66] J. Brown,et al. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. , 1987, The Biochemical journal.
[67] A. O’Brien,et al. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice , 1996, Infection and immunity.
[68] A. Melton,et al. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model , 1993, Infection and immunity.
[69] C. Ackerley,et al. A Major Fraction of Glycosphingolipids in Model and Cellular Cholesterol-containing Membranes Is Undetectable by Their Binding Proteins* , 2010, The Journal of Biological Chemistry.
[70] S. Homans,et al. Solution structure of the carbohydrate-binding B-subunit homopentamer of verotoxin VT-1 from E. coli , 1997, Nature Structural Biology.
[71] A. Caprioli,et al. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome , 2004, Cytometry. Part B, Clinical cytometry.
[72] A. Weiss,et al. Shiga Toxin Subtypes Display Dramatic Differences in Potency , 2011, Infection and Immunity.
[73] J. Samuel,et al. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality , 1994, Infection and immunity.
[74] J. Wells,et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. , 1983, The New England journal of medicine.
[75] K. Sandvig,et al. Furin-induced Cleavage and Activation of Shiga Toxin (*) , 1995, The Journal of Biological Chemistry.
[76] S. Lauwers,et al. Identification of New Verocytotoxin Type 2 Variant B-Subunit Genes in Human and Animal Escherichia coliIsolates , 1998, Journal of Clinical Microbiology.
[77] H. Mason,et al. Plant Cell-Based Intimin Vaccine Given Orally to Mice Primed with Intimin Reduces Time of Escherichia coli O157:H7 Shedding in Feces , 2004, Infection and Immunity.
[78] A. Caprioli,et al. A New Shiga Toxin 2 Variant (Stx2f) fromEscherichia coli Isolated from Pigeons , 2000, Applied and Environmental Microbiology.
[79] R. Dubos,et al. PREPARATION AND PROPERTIES OF SHIGA TOXIN AND TOXOID , 1946, The Journal of experimental medicine.
[80] D. Karpman,et al. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. , 2011, Blood.
[81] W. Yam,et al. A Newly Discovered Verotoxin Variant, VT2g, Produced by Bovine Verocytotoxigenic Escherichia coli , 2003, Applied and Environmental Microbiology.
[82] V. L. Tesh. The induction of apoptosis by Shiga toxins and ricin. , 2012, Current topics in microbiology and immunology.
[83] M. McKee,et al. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 , 1991, Infection and immunity.
[84] M. Nagata,et al. Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome. , 2001, Microbial pathogenesis.
[85] K. Sandvig,et al. Retrograde transport of protein toxins through the Golgi apparatus , 2013, Histochemistry and Cell Biology.
[86] C. Lingwood,et al. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. , 1992, Biochemistry.
[87] M. Thompson,et al. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. , 1982, The Journal of infectious diseases.
[88] D. Acheson,et al. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy , 2002, Pediatric Nephrology.
[89] L. Beutin,et al. Heterogeneity of the amino-acid sequences of Escherichia coli Shiga-like toxin type-I operons. , 1995, Gene.
[90] R. N. Smith,et al. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli. , 2006, The Journal of infectious diseases.
[91] P. Marsden,et al. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome , 2013, Virulence.
[92] C. Tacket,et al. Phase 1 Safety and Pharmacokinetic Study of Chimeric Murine-Human Monoclonal Antibody cαStx2 Administered Intravenously to Healthy Adult Volunteers , 2005, Antimicrobial Agents and Chemotherapy.
[93] Tetsuya Mori,et al. Activation of Src Family Kinase Yes Induced by Shiga Toxin Binding to Globotriaosyl Ceramide (Gb3/CD77) in Low Density, Detergent-insoluble Microdomains* , 1999, The Journal of Biological Chemistry.
[94] M. Donowitz,et al. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. , 2001, Journal of cell science.
[95] R J Read,et al. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. , 1998, Biochemistry.
[96] C. Lingwood,et al. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. , 2004, European journal of biochemistry.
[97] F. Scheutz,et al. Subtyping Method for Escherichia coli Shiga Toxin (Verocytotoxin) 2 Variants and Correlations to Clinical Manifestations , 2007, Journal of Clinical Microbiology.
[98] H. Conradi. Ueber lösliche, durch aseptische Autolyse erhaltene Giftstoffe von Ruhr- und Typhusbazillen , 1903 .
[99] C. Lingwood,et al. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. , 1991, The Journal of biological chemistry.
[100] H. Karch,et al. Identification, Characterization, and Distribution of a Shiga Toxin 1 Gene Variant (stx1c) in Escherichia coli Strains Isolated from Humans , 2002, Journal of Clinical Microbiology.
[101] L. Beutin,et al. Isolation of a Lysogenic Bacteriophage Carrying thestx1OX3 Gene, Which Is Closely Associated with Shiga Toxin-Producing Escherichia coli Strains from Sheep and Humans , 2001, Journal of Clinical Microbiology.
[102] K. Matsuoka,et al. Structural Analysis of the Interaction between Shiga Toxin B Subunits and Linear Polymers Bearing Clustered Globotriose Residues , 2006, Infection and Immunity.
[103] K. Kashiwagi,et al. Comparison of the modes of action of a Vero toxin (a Shiga-like toxin) from Escherichia coli, of ricin, and of alpha-sarcin. , 1992, Archives of biochemistry and biophysics.
[104] L. Teel,et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. , 2006, Vaccine.
[105] Kazuro Furukawa,et al. Targeted Disruption of Gb3/CD77 Synthase Gene Resulted in the Complete Deletion of Globo-series Glycosphingolipids and Loss of Sensitivity to Verotoxins* , 2006, Journal of Biological Chemistry.
[106] E. Mintz,et al. Emergence of Shiga toxin 1 genes within Shigella dysenteriae type 4 isolates from travelers returning from the Island of Hispañola. , 2007, The American journal of tropical medicine and hygiene.
[107] P. Kahn,et al. Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae. , 2011, Toxicon : official journal of the International Society on Toxinology.
[108] P. Manning,et al. Polymerase chain reaction amplification, cloning and sequencing of variant Escherichia coli Shiga-like toxin type II operons. , 1993, Microbial pathogenesis.
[109] M. Mehran,et al. Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.
[110] Richard J. H. Smith,et al. Familial Atypical Hemolytic Uremic Syndrome: A Review of Its Genetic and Clinical Aspects , 2012, Clinical & developmental immunology.
[111] D. Friedmann,et al. Molecular Basis of Differential B-Pentamer Stability of Shiga Toxins 1 and 2 , 2010, PloS one.
[112] C. Lingwood,et al. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology. , 2009, Kidney international.
[113] Stefano Morabito,et al. Multicenter Evaluation of a Sequence-Based Protocol for Subtyping Shiga Toxins and Standardizing Stx Nomenclature , 2012, Journal of Clinical Microbiology.
[114] T. Obrig,et al. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. , 1995, The Journal of infectious diseases.
[115] M. Saleem,et al. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome , 2014, Pediatric Nephrology.
[116] J. Gariépy,et al. The catalytic subunit of shiga-like toxin 1 interacts with ribosomal stalk proteins and is inhibited by their conserved C-terminal domain. , 2008, Journal of molecular biology.
[117] D. Leyva-Illades,et al. Differential Response of the Human Renal Proximal Tubular Epithelial Cell Line HK-2 to Shiga Toxin Types 1 and 2 , 2011, Infection and Immunity.
[118] M. Morigi,et al. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction , 2010, Pediatric Nephrology.
[119] A. O’Brien,et al. When a healthy diet turns deadly , 2013, Gut microbes.
[120] G. Armstrong,et al. Affinities of Shiga toxins 1 and 2 for univalent and oligovalent Pk-trisaccharide analogs measured by electrospray ionization mass spectrometry. , 2007, Glycobiology.
[121] T. L. Hale,et al. Cytotoxicity of Shigella dysenteriae 1 for cultured mammalian cells. , 1980, The American journal of clinical nutrition.
[122] H Nakajima,et al. Kinetic Analysis of Binding between Shiga Toxin and Receptor Glycolipid Gb3Cer by Surface Plasmon Resonance* , 2001, The Journal of Biological Chemistry.
[123] Mark A. Smith,et al. Dietary choice affects Shiga toxin-producing Escherichia coli (STEC) O157:H7 colonization and disease , 2013, Proceedings of the National Academy of Sciences.
[124] N. Taneja,et al. Detection of Shiga toxin variants among Shiga toxin–forming Escherichia coli isolates from animal stool, meat and human stool samples in India , 2012, Journal of applied microbiology.
[125] J. Mekalanos,et al. Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[126] C. Lingwood,et al. Membrane cytosolic translocation of verotoxin A1 subunit in target cells. , 2007, Microbiology.
[127] C. MacKenzie,et al. A Mutational Analysis of the Globotriaosylceramide-binding Sites of Verotoxin VT1* , 2002, The Journal of Biological Chemistry.
[128] A. O’Brien,et al. Elastase in Intestinal Mucus Enhances the Cytotoxicity of Shiga Toxin Type 2d* , 2000, The Journal of Biological Chemistry.
[129] S. Formal,et al. ESCHERICHIA COLI 0157:H7 STRAINS ASSOCIATED WITH HAEMORRHAGIC COLITIS IN THE UNITED STATES PRODUCE A SHIGELLA DYSENTERIAE 1 (SHIGA) LIKE CYTOTOXIN , 1983, The Lancet.
[130] M. James,et al. Binding of adenine to Stx2, the protein toxin from Escherichia coli O157:H7. , 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.
[131] R. Read,et al. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit , 1999, Molecular microbiology.
[132] S. High,et al. Eeyarestatin 1 Interferes with Both Retrograde and Anterograde Intracellular Trafficking Pathways , 2011, PloS one.
[133] A. Weiss,et al. Escherichia coli Serogroup O107/O117 Lipopolysaccharide Binds and Neutralizes Shiga Toxin 2 , 2004, Journal of bacteriology.
[134] M. Petric,et al. SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.
[135] S. Yamasaki,et al. Genetic and Immunological Analysis of a Novel Variant of Shiga Toxin 1 from Bovine Escherichia coli Strains and Development of Bead‐ELISA to Detect the Variant Toxin , 2003, Microbiology and immunology.
[136] J. Kaper,et al. Shiga toxin binding in normal and inflamed human intestinal mucosa. , 2007, Microbes and infection.
[137] J. Rodriguez-Canales,et al. Human Intestinal Tissue and Cultured Colonic Cells Contain Globotriaosylceramide Synthase mRNA and the Alternate Shiga Toxin Receptor Globotetraosylceramide , 2010, Infection and Immunity.
[138] C. Pai,et al. Experimental infection of infant rabbits with verotoxin-producing Escherichia coli , 1986, Infection and immunity.
[139] C. Lingwood,et al. Globotetraosylceramide is recognized by the pig edema disease toxin. , 1989, The Journal of biological chemistry.